Skip to main content
SpringerLink
Log in

Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM

  • Unknown
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. SGLT-2 inhibitors: dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, and luseogliflozin

  2. SGLT-1/2 inhibitors: licogliflozin and sotagliflozin

Reference

  • Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials American Journal of Cardiovascular Drugs : 29 Mar 2022. Available from: URL: https://doi.org/10.1007/s40256-022-00528-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM. Reactions Weekly 1900, 7 (2022). https://doi.org/10.1007/s40278-022-12359-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-12359-9

Search

Navigation